Figure 2. Predicted 10-Year Change in Concentrations of Total Tau (T‐Tau), Neurofilament Light Chain (NfL), and Glial Fibrillary Acidic Protein (GFAP) Among Those Diagnosed With Clinical AD and No Cognitive Impairment in a Biracial Population Sample.

Longitudinal change in t‐tau (A), NfL (B), and GFAP (C) among those who developed clinical AD and those who did not develop cognitive impairment. The models adjusted for age, female sex, Black race, education, and the ApoE4 allele with log10-transformed serum biomarkers concentrations as outcome measures.